当前位置：
X-MOL 学术
›
Hepatology
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial
Hepatology ( IF 13.5 ) Pub Date : 2022-09-09 , DOI: 10.1002/hep.32778 Ryan W Dellinger 1 , Holly E Holmes 1 , Tina Hu-Seliger 1 , Rodney W Butt 2 , Stephen A Harrison 3 , Dariush Mozaffarian 4 , Oliver Chen 4, 5 , Leonard Guarente 1, 6
Hepatology ( IF 13.5 ) Pub Date : 2022-09-09 , DOI: 10.1002/hep.32778 Ryan W Dellinger 1 , Holly E Holmes 1 , Tina Hu-Seliger 1 , Rodney W Butt 2 , Stephen A Harrison 3 , Dariush Mozaffarian 4 , Oliver Chen 4, 5 , Leonard Guarente 1, 6
Affiliation
|
The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
中文翻译：
烟酰胺核苷和紫檀芪可降低 NAFLD 中肝脏炎症标志物：一项双盲、安慰剂对照临床试验
NAFLD 的患病率在全球范围内不断增加，并有可能成为慢性肝病的最常见原因。迫切需要预防和治疗 NAFLD 的策略。
更新日期：2022-09-09
中文翻译：
烟酰胺核苷和紫檀芪可降低 NAFLD 中肝脏炎症标志物：一项双盲、安慰剂对照临床试验
NAFLD 的患病率在全球范围内不断增加，并有可能成为慢性肝病的最常见原因。迫切需要预防和治疗 NAFLD 的策略。
京公网安备 11010802027423号